A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma
Kidney NeoplasmsCarcinoma3 moreThe purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.
Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal...
CarcinomaRenal Cell MetastasisTo evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic renal cell carcinoma (RCC) when administered in a continuous treatment regimen
A Study of Avastin (Bevacizumab) in Combination With Low-Dose-Interferon in Patients With Metastatic...
Renal Cell CancerThis single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma. Patients will receive Avastin (10mg/kg iv) every 2 weeks in combination with a low dose of interferon alfa-2a (3 MIU sc three times per week (t.i.w.). The anticipated time on study treatment is until disease progression, and the target sample size is 100-500 individuals.
RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
Renal Cell CarcinomaTo assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
Kidney NeoplasmsThe study is designed to demonstrate that axitinib (AG-013736) is superior to sorafenib in delaying tumor progression in patients with metastatic renal cell cancer.
GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma
CarcinomaRenal CellPhase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
Clear Cell Renal Cell CarcinomaThis phase I/II trial will evaluate the bevacizumab/erlotinib combination with the addition of imatinib (Gleevec). The combined inhibition greatly enhances the anti-tumor effects. Although the safety of the bevacizumab/erlotinib/imatinib combination has not yet been demonstrated, the mild to moderate side effects of all of these agents are not predicted to cause prohibitive toxicity. A brief phase I portion will be included in this trial, to optimize doses of the 3 agents prior to proceeding with the phase II trial.
Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be...
Recurrent Renal Cell CarcinomaStage IV Renal Cell CancerThis phase II trial studies how well cediranib maleate works in treating patients with recurrent or metastatic kidney cancer that cannot be removed by surgery. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study of SU011248 in Patients With Advanced Kidney Cancer
CarcinomaRenal CellTo determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with metastatic Renal Cell Cancer (RCC).
Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer
Kidney CancerRATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.